Free Trial
→ Trump’s Bitcoin Reserve is No Accident… (From Crypto 101 Media) (Ad) Buy AGIO Stock  Free AGIO Stock Alerts

Agios Pharmaceuticals (AGIO) Financials

Agios Pharmaceuticals logo
$30.08 -0.09 (-0.30%)
As of 03:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Agios Pharmaceuticals

Annual Income Statements for Agios Pharmaceuticals

This table shows Agios Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Income / (Loss) Attributable to Common Shareholders		 674 -352 -232 1,605 -327 -411 -346 -315 -198 -118 -54
Consolidated Net Income / (Loss)		 674 -352 -232 1,605 -327 -411 -346 -315 -198 -118 -54
Net Income / (Loss) Continuing Operations		 680 -352 -232 -357 -329 -301 -346 -315 -198 -118 -54
Total Pre-Tax Income 		718 -352 -232 -357 -329 -301 -346 -315 -198 -118 -54
Total Operating Income		 -426 -391 -389 -378 -336 -316 -362 -321 -201 -119 -54
Total Gross Profit		 32 24 13 0.00 0.00 0.00 93 43 70 59 65
Total Revenue		 36 27 14 0.00 0.00 0.00 94 43 70 59 65
Operating Revenue		 36 27 14 0.00 - - 94 43 70 59 65
Total Cost of Revenue		 4.17 2.88 1.70 0.00 0.00 0.00 1.40 0.00 0.00 0.00 0.00
Operating Cost of Revenue		 4.17 2.88 1.70 0.00 - - 1.40 0.00 0.00 - -
Total Operating Expenses		 458 415 402 378 336 316 455 364 271 178 119
Selling, General & Admin Expense		 157 120 122 121 115 102 114 71 51 36 19
Research & Development Expense		 301 296 280 257 221 214 341 293 220 142 100
Total Other Income / (Expense), net		 1,137 39 157 22 6.61 15 16 6.12 2.51 0.97 0.20
Interest & Investment Income		 48 33 23 7.48 6.61 15 16 6.12 2.51 0.97 0.20
Other Income / (Expense), net		 1,089 6.06 135 14 0.00 - - - - - -
Income Tax Expense		 44 0.00 0.00 - - - - - - - -0.43
Other Gains / (Losses), net		 6.49 - - - - 0.00 - - - - -
Basic Earnings per Share		 $11.86 ($6.33) ($4.23) $26.55 ($4.74) ($6.86) ($6.03) ($6.75) ($5.07) ($3.15) ($1.59)
Weighted Average Basic Shares Outstanding		 56.81M 55.65M 54.79M 60.45M 69.00M 59.99M 57.42M 46.59M 39.13M 37.43M 33.67M
Diluted Earnings per Share		 $11.64 ($6.33) ($4.23) $26.55 ($4.74) ($6.86) ($6.03) ($6.75) ($5.07) ($3.15) ($1.59)
Weighted Average Diluted Shares Outstanding		 57.89M 55.65M 54.79M 60.45M 69.00M 59.99M 57.42M 46.59M 39.13M 37.43M 33.67M
Weighted Average Basic & Diluted Shares Outstanding		 57.30M 56.19M 55.29M 54.64M 69.00M 59.99M 57.42M 46.59M 39.13M 37.43M 33.67M

Quarterly Income Statements for Agios Pharmaceuticals

This table shows Agios Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -89 -97 948 -96 -82 -96 -91 -84 -81 37 -82
Consolidated Net Income / (Loss)		 -89 -97 948 -96 -82 -96 -91 -84 -81 37 -82
Net Income / (Loss) Continuing Operations		 -89 -92 950 -96 -82 -96 -91 -84 -81 37 -82
Total Pre-Tax Income 		-91 -104 1,001 -96 -83 -96 -91 -84 -81 39 -82
Total Operating Income		 -107 -125 -103 -106 -92 -106 -101 -94 -91 -99 -91
Total Gross Profit		 7.64 9.47 8.18 7.12 7.56 6.52 6.77 5.60 5.06 3.90 3.00
Total Revenue		 8.73 11 8.96 8.62 8.19 7.10 7.40 6.71 5.61 4.31 3.52
Operating Revenue		 8.73 11 8.96 8.62 8.19 7.10 7.40 6.71 5.61 4.31 3.52
Total Cost of Revenue		 1.09 1.26 0.78 1.50 0.63 0.59 0.63 1.11 0.55 0.41 0.52
Operating Cost of Revenue		 1.09 1.26 0.78 1.50 0.63 0.59 0.63 1.11 0.55 0.41 0.52
Total Operating Expenses		 114 135 111 113 100 113 108 99 96 103 94
Selling, General & Admin Expense		 42 52 39 36 31 35 26 30 28 33 29
Research & Development Expense		 73 83 72 77 69 77 82 69 67 70 65
Total Other Income / (Expense), net		 16 16 1,102 9.70 8.89 10 9.57 9.89 9.60 139 9.34
Interest & Investment Income		 16 18 13 8.12 8.89 8.62 8.38 8.25 8.09 6.49 8.26
Other Gains / (Losses), net		 1.25 - 1.65 - 1.63 - - - - - -
Basic Earnings per Share		 ($1.55) ($1.65) $16.65 ($1.69) ($1.45) ($1.71) ($1.64) ($1.51) ($1.47) $0.68 ($1.49)
Weighted Average Basic Shares Outstanding		 57.46M 56.81M 56.94M 56.80M 56.38M 55.65M 55.80M 55.60M 55.27M 54.79M 54.84M
Diluted Earnings per Share		 ($1.55) ($1.44) $16.22 ($1.69) ($1.45) ($1.71) ($1.64) ($1.51) ($1.47) $0.68 ($1.49)
Weighted Average Diluted Shares Outstanding		 57.46M 57.89M 58.43M 56.80M 56.38M 55.65M 55.80M 55.60M 55.27M 54.79M 54.84M
Weighted Average Basic & Diluted Shares Outstanding		 57.92M 57.30M 57.03M 56.89M 56.77M 56.19M 55.89M 55.74M 55.58M 55.29M 54.94M

Annual Cash Flow Statements for Agios Pharmaceuticals

This table details how cash moves in and out of Agios Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Change in Cash & Equivalents		 -12 -51 -64 76 47 10 -32 -58 89 58 -58
Net Cash From Operating Activities		 -390 -296 -309 -407 -291 -371 -304 -285 39 -77 -59
Net Cash From Continuing Operating Activities		 -390 -296 -309 -314 -244 -236 -304 -285 39 -77 -59
Net Income / (Loss) Continuing Operations		 674 -352 -232 -357 -329 -301 -346 -315 -198 -118 -54
Consolidated Net Income / (Loss)		 674 -352 -232 1,605 -327 -411 -346 -315 -198 -118 -54
Depreciation Expense		 5.65 6.62 8.56 9.24 9.79 8.09 7.17 6.43 5.70 3.34 1.37
Amortization Expense		 -14 -5.05 -1.20 6.95 3.02 -3.20 -3.84 -0.01 0.77 0.54 0.54
Non-Cash Adjustments To Reconcile Net Income		 -1,050 60 -69 63 71 61 67 49 45 30 12
Changes in Operating Assets and Liabilities, net		 -4.76 -5.39 -16 -37 1.97 -0.41 -28 -26 185 6.64 -19
Net Cash From Investing Activities		 363 240 243 1,249 76 91 -274 -58 -119 128 -333
Net Cash From Continuing Investing Activities		 363 240 243 -554 77 92 -274 -58 -119 128 -333
Purchase of Property, Plant & Equipment		 -1.69 -1.00 -4.88 -5.74 -14 -12 -6.99 -4.63 -9.92 -20 -2.22
Purchase of Investments		 -1,542 -418 -1,031 -1,378 -557 -489 -933 -689 -506 -353 -837
Sale of Property, Plant & Equipment		 0.04 1.33 0.96 0.00 0.00 - - - - - -
Divestitures		 200 0.00 0.00 - - - - - - - -
Sale and/or Maturity of Investments		 818 675 1,146 830 648 592 666 635 397 502 506
Other Investing Activities, net		 889 -18 132 0.00 0.00 - - - - - 0.57
Net Cash From Financing Activities		 14 5.43 2.35 -766 262 290 546 285 170 6.37 335
Net Cash From Continuing Financing Activities		 14 5.43 2.35 -766 11 290 546 285 170 6.37 335
Issuance of Common Equity		 14 5.43 2.68 37 11 290 547 284 170 6.58 334
Other Financing Activities, net		 0.00 0.00 -0.33 -0.58 -0.34 -0.11 0.00 0.64 - - 2.30
Cash Income Taxes Paid		 43 1.57 0.00 16 0.00 0.00 - - - - 5.98

Quarterly Cash Flow Statements for Agios Pharmaceuticals

This table details how cash moves in and out of Agios Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 2.72 -177 169 -34 31 24 -20 -19 -35 17 34
Net Cash From Operating Activities		 -111 -133 -84 -73 -100 -72 -62 -67 -95 -66 -71
Net Cash From Continuing Operating Activities		 -111 -133 -84 -73 -100 -72 -62 -67 -95 -66 -71
Net Income / (Loss) Continuing Operations		 -89 -97 948 -96 -82 -96 -91 -84 -81 37 -82
Consolidated Net Income / (Loss)		 -89 -97 948 -96 -82 -96 -91 -84 -81 37 -82
Depreciation Expense		 1.28 1.37 1.35 1.59 1.35 1.40 1.62 1.81 1.79 1.81 1.98
Amortization Expense		 -1.35 -5.62 -3.73 -2.61 -2.53 -0.39 1.08 -2.96 -2.78 -1.92 -0.66
Non-Cash Adjustments To Reconcile Net Income		 14 10 -1,086 18 8.20 13 20 18 9.28 -106 6.04
Changes in Operating Assets and Liabilities, net		 -37 -42 57 6.48 -25 9.10 7.46 0.50 -22 3.67 3.03
Net Cash From Investing Activities		 113 -49 251 37 125 96 39 47 58 83 104
Net Cash From Continuing Investing Activities		 113 -49 251 37 125 96 39 47 58 83 104
Purchase of Property, Plant & Equipment		 -0.77 -0.97 -0.42 -0.16 -0.14 -0.23 -0.37 0.00 -0.40 -0.11 -0.04
Purchase of Investments		 -175 -198 -996 -105 -244 -90 -95 -104 -128 -249 -174
Sale of Property, Plant & Equipment		 0.00 - - - 0.04 - 1.18 - 0.15 0.96 -
Sale and/or Maturity of Investments		 288 150 158 142 369 186 151 151 186 199 279
Net Cash From Financing Activities		 1.62 4.84 2.64 1.10 5.86 0.85 1.88 0.24 2.47 0.02 1.19
Net Cash From Continuing Financing Activities		 1.62 4.84 2.64 1.10 5.86 0.85 1.88 0.24 2.47 0.02 1.19
Issuance of Common Equity		 1.62 4.84 2.64 1.10 5.86 0.85 1.88 0.24 2.47 0.11 1.27
Cash Income Taxes Paid		 0.19 44 -0.03 -0.08 -0.53 -0.02 0.79 0.80 0.00 -1.94 0.10

Annual Balance Sheets for Agios Pharmaceuticals

This table presents Agios Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Total Assets		 1,663 937 1,239 1,438 853 891 858 614 619 420 492
Total Current Assets		 966 834 833 1,064 637 612 614 445 560 337 360
Cash & Equivalents		 76 88 139 203 127 81 71 103 161 72 14
Short-Term Investments		 817 689 644 817 445 484 515 321 381 245 328
Accounts Receivable		 4.11 2.81 2.21 4.38 0.00 8.95 5.08 0.00 3.43 12 8.83
Inventories, net		 28 19 8.49 0.00 - 7.33 0.87 0.00 - - -
Prepaid Expenses		 40 35 39 40 16 24 17 18 10 8.73 4.81
Plant, Property, & Equipment, net		 12 15 23 29 31 31 24 24 25 23 6.39
Total Noncurrent Assets		 686 88 383 345 185 248 220 145 34 60 126
Long-Term Investments		 638 29 314 266 98 153 220 144 32 59 125
Other Noncurrent Operating Assets		 48 58 69 78 85 94 0.24 0.89 1.62 0.61 0.59
Total Liabilities & Shareholders' Equity		 1,663 937 1,239 1,438 853 891 858 614 619 420 492
Total Liabilities		 122 126 138 146 453 250 171 239 261 75 68
Total Current Liabilities		 81 68 63 60 94 93 94 95 88 53 61
Accounts Payable		 17 9.78 19 17 18 22 18 23 17 15 11
Accrued Expenses		 47 43 30 32 31 53 42 34 32 16 14
Current Deferred & Payable Income Tax Liabilities		 0.87 0.00 - - - - - - - - -
Other Current Liabilities		 17 15 14 11 7.41 6.92 33 38 - - 0.01
Total Noncurrent Liabilities		 41 58 75 86 359 157 77 144 172 22 6.45
Other Noncurrent Operating Liabilities		 41 58 75 86 97 106 60 126 - - -
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,541 811 1,101 1,292 400 641 688 376 359 345 424
Total Preferred & Common Equity		 1,541 811 1,101 1,292 400 641 688 376 359 345 424
Preferred Stock		 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,541 811 1,101 1,292 400 641 688 376 359 345 424
Common Stock		 2,494 2,437 2,386 2,334 2,243 2,156 1,794 1,175 842 630 591
Retained Earnings		 -149 -823 -471 -239 -1,843 -1,516 -1,105 -798 -483 -285 -167
Treasury Stock		 -802 -802 -802 -802 0.00 - - - - - -
Accumulated Other Comprehensive Income / (Loss)		 -1.52 -0.44 -13 -1.20 0.11 0.20 -2.17 -1.39 -0.31 -0.32 -0.06

Quarterly Balance Sheets for Agios Pharmaceuticals

This table presents Agios Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 1,556 1,792 773 850 1,007 1,085 1,151 1,180
Total Current Assets		 969 1,074 632 664 704 757 792 785
Cash & Equivalents		 79 254 85 119 64 85 104 122
Short-Term Investments		 814 751 485 479 583 618 635 605
Accounts Receivable		 3.34 3.12 3.76 3.45 1.18 2.25 1.78 5.59
Inventories, net		 30 26 24 23 17 16 11 5.18
Prepaid Expenses		 42 40 35 39 38 37 39 46
Plant, Property, & Equipment, net		 11 12 13 14 17 20 21 25
Total Noncurrent Assets		 576 706 128 172 286 308 338 370
Long-Term Investments		 531 656 75 116 225 244 272 298
Other Noncurrent Operating Assets		 45 50 53 56 61 64 66 72
Total Liabilities & Shareholders' Equity		 1,556 1,792 773 850 1,007 1,085 1,151 1,180
Total Liabilities		 89 165 113 106 120 121 115 130
Total Current Liabilities		 52 119 63 52 58 55 45 54
Accounts Payable		 14 17 10 11 13 12 8.66 10
Accrued Expenses		 21 33 37 25 30 29 22 30
Current Deferred & Payable Income Tax Liabilities		 0.68 53 - - - - - -
Other Current Liabilities		 17 16 16 15 15 14 14 13
Total Noncurrent Liabilities		 37 46 50 54 62 66 70 77
Other Noncurrent Operating Liabilities		 37 46 50 54 62 66 70 77
Total Equity & Noncontrolling Interests		 1,467 1,627 661 744 887 964 1,037 1,050
Total Preferred & Common Equity		 1,467 1,627 661 744 887 964 1,037 1,050
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Total Common Equity		 1,467 1,627 661 744 887 964 1,037 1,050
Common Stock		 2,507 2,478 2,464 2,452 2,422 2,411 2,399 2,375
Retained Earnings		 -238 -52 -1,000 -904 -727 -635 -552 -507
Treasury Stock		 -802 -802 -802 -802 -802 -802 -802 -802
Accumulated Other Comprehensive Income / (Loss)		 0.37 3.42 -1.05 -1.09 -5.90 -8.87 -8.41 -15

Annual Metrics And Ratios for Agios Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Agios Pharmaceuticals' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 36.07% 88.36% 0.00% 0.00% 0.00% -100.00% 119.45% -38.46% 18.22% -9.55% 155.82%
EBITDA Growth		 270.52% -55.36% 28.96% -7.64% -3.77% 13.30% -14.24% -61.62% -69.41% -119.84% -40.55%
EBIT Growth		 272.12% -51.48% 30.09% -8.36% -6.21% 12.75% -12.99% -59.61% -69.32% -119.27% -39.22%
NOPAT Growth		 -45.78% -0.63% -2.81% -12.65% -6.21% 12.75% -12.99% -59.61% -69.32% -119.27% -39.22%
Net Income Growth		 291.35% -51.89% -114.45% 590.18% 20.44% -18.91% -9.97% -58.55% -68.58% -120.04% -35.77%
EPS Growth		 283.89% -49.65% -115.93% 660.13% 30.90% -13.76% 10.67% -33.14% -60.95% -98.11% 43.82%
Operating Cash Flow Growth		 -31.68% 4.34% 24.02% -40.09% 21.55% -21.75% -6.73% -839.67% 150.11% -29.65% -5.24%
Free Cash Flow Firm Growth		 -46.89% -1.69% 7.49% -0.65% -10.52% 19.94% -32.68% -668.54% 145.60% -65.03% -18.23%
Invested Capital Growth		 91.69% 21.85% -34.77% 127.33% 72.01% 35.02% 38.68% 10.57% -598.21% 28.53% 31.60%
Revenue Q/Q Growth		 11.03% 11.62% 43.40% 0.00% 100.00% -100.00% 27.25% -23.00% 30.73% -12.46% 13.73%
EBITDA Q/Q Growth		 259.44% 0.02% 35.56% -1.56% -36.80% 24.57% -2.05% -11.75% -8.85% -13.22% -38.58%
EBIT Q/Q Growth		 263.01% -0.27% 35.53% -1.41% -36.30% 24.11% -1.75% -11.36% -8.95% -13.56% -36.53%
NOPAT Q/Q Growth		 1.84% -1.85% 1.43% -5.43% -36.30% 24.11% -1.75% -11.36% -8.95% -13.56% -36.53%
Net Income Q/Q Growth		 -0.09% -60.32% 36.13% 0.19% 1.41% -2.63% -1.02% -11.24% -8.69% -13.45% -36.41%
EPS Q/Q Growth		 2.37% -60.66% -80.77% 17.63% 3.66% -0.15% 3.83% -7.31% -5.41% -12.10% -174.65%
Operating Cash Flow Q/Q Growth		 -18.43% -2.18% 5.48% -9.31% 13.20% -5.53% 0.09% -8.87% -34.92% -41.99% 8.96%
Free Cash Flow Firm Q/Q Growth		 -12.61% -5.97% 10.46% 40.59% -1,177.58% 17.33% -1.54% -7.11% -27.13% -34.38% 0.00%
Invested Capital Q/Q Growth		 126.27% -67.79% -84.17% 508.51% 91.14% 16.90% 0.26% -0.17% 2.79% 4.76% -42.95%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 88.59% 89.26% 88.03% 0.00% 0.00% 0.00% 98.52% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 1,793.43% -1,431.09% -1,735.11% 0.00% 0.00% 0.00% -380.50% -730.91% -278.30% -194.22% -79.91%
Operating Margin		 -1,166.47% -1,459.52% -2,732.07% 0.00% 0.00% 0.00% -384.03% -745.84% -287.57% -200.78% -82.83%
EBIT Margin		 1,817.63% -1,436.95% -1,786.83% 0.00% 0.00% 0.00% -384.03% -745.84% -287.57% -200.78% -82.83%
Profit (Net Income) Margin		 1,845.92% -1,312.63% -1,627.82% 0.00% 0.00% 0.00% -366.61% -731.60% -283.97% -199.14% -81.86%
Tax Burden Percent		 93.84% 100.00% 100.00% -450.12% 99.41% 136.52% 100.00% 100.00% 100.00% 100.00% 99.21%
Interest Burden Percent		 108.23% 91.35% 91.10% 97.95% 98.03% 95.30% 95.46% 98.09% 98.75% 99.18% 99.63%
Effective Tax Rate		 6.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -5,883.24% -6,465.52% -5,627.29% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -5,975.03% -6,457.32% -5,630.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 5,940.53% 6,428.68% 5,607.92% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 57.29% -36.83% -19.38% 189.74% -62.95% -61.97% -65.10% -85.73% -56.41% -30.60% -19.25%
Cash Return on Invested Capital (CROIC)		 -5,946.11% -6,485.22% -5,585.20% -4,987.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 51.02% -35.43% -19.01% 0.00% 0.00% 0.00% -49.22% -52.01% -38.68% -26.03% -15.62%
Return on Assets (ROA)		 51.82% -32.36% -17.32% 0.00% 0.00% 0.00% -46.99% -51.02% -38.20% -25.82% -15.44%
Return on Common Equity (ROCE)		 57.29% -36.83% -19.38% 189.74% -62.95% -61.97% -65.10% -85.73% -56.41% -30.60% -19.25%
Return on Equity Simple (ROE_SIMPLE)		 43.72% -43.41% -21.06% 124.21% -81.94% -64.24% -50.33% -83.80% -55.35% -34.11% -12.61%
Net Operating Profit after Tax (NOPAT)		 -400 -274 -272 -265 -235 -221 -254 -225 -141 -83 -38
NOPAT Margin		 -1,094.58% -1,021.66% -1,912.45% 0.00% 0.00% 0.00% -268.82% -522.09% -201.30% -140.55% -57.98%
Net Nonoperating Expense Percent (NNEP)		 91.79% -8.20% 3.40% 219.04% -16.21% -24.97% -13.44% -15.79% -12.17% -8.22% -4.72%
Return On Investment Capital (ROIC_SIMPLE)		 -25.93% -33.79% -24.74% - - - - - - - -
Cost of Revenue to Revenue		 11.41% 10.74% 11.97% 0.00% 0.00% 0.00% 1.48% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 429.57% 447.02% 854.45% 0.00% 0.00% 0.00% 120.93% 165.36% 72.56% 60.88% 29.25%
R&D to Revenue		 825.49% 1,101.76% 1,965.66% 0.00% 0.00% 0.00% 361.62% 680.48% 315.00% 239.90% 153.57%
Operating Expenses to Revenue		 1,255.06% 1,548.78% 2,820.11% 0.00% 0.00% 0.00% 482.55% 845.84% 387.57% 300.78% 182.83%
Earnings before Interest and Taxes (EBIT)		 663 -385 -254 -364 -336 -316 -362 -321 -201 -119 -54
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 655 -384 -247 -348 -323 -311 -359 -314 -195 -115 -52
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.22 1.53 1.40 1.38 7.51 4.39 3.90 7.42 4.89 7.08 9.16
Price to Tangible Book Value (P/TBV)		 1.22 1.53 1.40 1.38 7.51 4.39 3.90 7.42 4.89 7.08 9.16
Price to Revenue (P/Rev)		 51.35 46.40 108.35 0.00 0.00 0.00 28.42 64.80 25.09 41.33 59.46
Price to Earnings (P/E)		 2.78 0.00 0.00 1.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 35.95% 0.00% 0.00% 89.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 38.32 94.14 116.69 85.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 9.37 16.34 31.31 0.00 0.00 0.00 19.89 51.60 16.88 34.98 52.30
Enterprise Value to EBITDA (EV/EBITDA)		 0.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 30.59 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 27.12 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.99 -1.00 -1.00 -1.01 -1.09 -1.15 -1.29 -1.55 -1.35 -1.10 -1.19
Leverage Ratio		 1.11 1.14 1.12 1.35 1.68 1.32 1.39 1.68 1.48 1.19 1.25
Compound Leverage Factor		 1.20 1.04 1.02 1.33 1.64 1.26 1.32 1.65 1.46 1.18 1.24
Debt to Total Capital		 0.00% 0.00% 0.00% 0.02% 0.08% 0.11% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.02% 0.08% 0.11% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 99.98% 99.92% 99.90% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 3.70 2.07 2.30 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 4.86 2.85 3.24 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 11.05 4.35 6.26 7.12 0.41 3.89 7.06 4.21 2.90 18.63 34.54
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 11.90 12.27 13.30 17.79 6.74 6.59 6.56 4.69 6.33 6.38 5.89
Quick Ratio		 11.06 11.47 12.54 17.12 6.07 6.18 6.31 4.47 6.16 6.21 5.74
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -404 -275 -270 -292 -290 -263 -328 -247 43 -95 -58
Operating Cash Flow to CapEx		 -23,698.54% 0.00% -7,900.89% -7,094.93% -2,061.24% -3,081.33% -4,357.59% -6,164.51% 388.93% -381.62% -2,678.38%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.03 0.02 0.01 0.00 0.00 0.00 0.13 0.07 0.13 0.13 0.19
Accounts Receivable Turnover		 10.55 10.70 4.33 0.00 0.00 0.00 0.00 0.00 9.30 5.79 14.05
Inventory Turnover		 0.18 0.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 2.70 1.40 0.55 0.00 0.00 0.00 3.87 1.73 2.88 3.99 12.89
Accounts Payable Turnover		 0.32 0.20 0.10 0.00 0.00 0.00 0.07 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 34.60 34.13 84.38 0.00 0.00 0.00 0.00 0.00 39.24 63.05 25.97
Days Inventory Outstanding (DIO)		 2,045.93 1,746.32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 1,157.79 1,798.77 3,782.38 0.00 0.00 0.00 5,310.01 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 922.73 -18.32 -3,698.00 0.00 0.00 0.00 -5,310.01 0.00 39.24 63.05 25.97
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 8.93 4.66 3.82 5.86 -21 -77 -118 -192 -215 -31 -43
Invested Capital Turnover		 5.37 6.33 2.94 0.00 0.00 0.00 -0.61 -0.21 -0.57 -1.60 -1.23
Increase / (Decrease) in Invested Capital		 4.27 0.84 -2.04 27 55 41 74 23 -184 12 20
Enterprise Value (EV)		 342 438 446 499 2,331 2,095 1,877 2,220 1,180 2,068 3,418
Market Capitalization		 1,874 1,245 1,543 1,785 3,001 2,812 2,683 2,787 1,753 2,444 3,886
Book Value per Share		 $27.02 $14.51 $20.03 $23.79 $5.77 $10.88 $11.82 $7.70 $8.53 $9.17 $12.24
Tangible Book Value per Share		 $27.02 $14.51 $20.03 $23.79 $5.77 $10.88 $11.82 $7.70 $8.53 $9.17 $12.24
Total Capital		 1,541 811 1,101 1,292 400 641 688 376 359 345 424
Total Debt		 0.00 0.00 0.00 0.28 0.33 0.67 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.28 0.33 0.67 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1,532 -806 -1,097 -1,286 -670 -717 -805 -568 -574 -376 -467
Capital Expenditures (CapEx)		 1.65 -0.33 3.92 5.74 14 12 6.99 4.63 9.92 20 2.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.27 -11 -13 -16 -31 -46 -65 -74 -70 -33 -44
Debt-free Net Working Capital (DFNWC)		 884 766 770 1,004 542 519 520 350 471 284 298
Net Working Capital (NWC)		 884 766 770 1,004 542 519 520 350 471 284 298
Net Nonoperating Expense (NNE)		 -1,073 78 -41 -1,870 92 190 92 90 58 35 16
Net Nonoperating Obligations (NNO)		 -1,532 -806 -1,097 -1,286 -421 -717 -805 -568 -574 -376 -467
Total Depreciation and Amortization (D&A)		 -8.83 1.57 7.37 16 13 4.89 3.34 6.42 6.47 3.88 1.91
Debt-free, Cash-free Net Working Capital to Revenue		 -25.39% -41.19% -91.12% 0.00% 0.00% 0.00% -68.89% -171.16% -99.95% -55.08% -66.72%
Debt-free Net Working Capital to Revenue		 2,423.27% 2,855.31% 5,408.31% 0.00% 0.00% 0.00% 551.22% 814.49% 674.55% 481.13% 456.65%
Net Working Capital to Revenue		 2,423.27% 2,855.31% 5,408.31% 0.00% 0.00% 0.00% 551.22% 814.49% 674.55% 481.13% 456.65%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $11.86 ($6.33) ($4.23) $26.55 ($4.74) ($6.86) ($6.03) ($6.75) ($5.07) ($3.15) ($1.59)
Adjusted Weighted Average Basic Shares Outstanding		 56.81M 55.65M 54.79M 60.45M 69.60M 68.51M 58.40M 57.33M 42.23M 37.85M 37.22M
Adjusted Diluted Earnings per Share		 $11.64 ($6.33) ($4.23) $26.55 ($4.74) ($6.86) ($6.03) ($6.75) ($5.07) ($3.15) ($1.59)
Adjusted Weighted Average Diluted Shares Outstanding		 57.89M 55.65M 54.79M 60.45M 69.60M 68.51M 58.40M 57.33M 42.23M 37.85M 37.22M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($4.74) ($6.86) ($6.03) ($6.75) ($5.07) ($3.15) ($1.59)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 57.30M 56.19M 55.29M 54.64M 69.00M 59.99M 57.42M 46.59M 39.13M 37.43M 33.67M
Normalized Net Operating Profit after Tax (NOPAT)		 -400 -274 -272 -265 -235 -221 -254 -225 -141 -83 -38
Normalized NOPAT Margin		 -1,094.58% -1,021.66% -1,912.45% 0.00% 0.00% 0.00% -268.82% -522.09% -201.30% -140.55% -57.98%
Pre Tax Income Margin		 1,967.15% -1,312.63% -1,627.82% 0.00% 0.00% 0.00% -366.61% -731.60% -283.97% -199.14% -82.51%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 50.01% 0.00% 0.00% 0.00% 0.00% 0.00% -0.18% 0.00%

Quarterly Metrics And Ratios for Agios Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Agios Pharmaceuticals' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 6.56% 51.06% 21.15% 28.35% 46.00% 64.80% 110.44% 20.24% 574.16% 0.00% 0.00%
EBITDA Growth		 -14.42% -24.85% 1,114.41% -12.92% -3.50% -4.31% -9.37% 0.60% 7.61% 1.71% -4.29%
EBIT Growth		 -15.81% -19.58% 1,089.30% -13.23% -3.33% -5.44% -10.77% 4.41% 11.90% 5.39% -0.96%
NOPAT Growth		 -15.81% -17.65% -37.84% -12.93% -1.61% 24.99% -10.77% 4.04% 10.41% -35.15% 0.07%
Net Income Growth		 -9.49% -0.61% 1,137.97% -14.69% -0.66% -362.66% -11.72% 8.71% 14.51% 138.60% 7.91%
EPS Growth		 -6.90% 15.79% 1,089.02% -11.92% 1.36% -351.47% -10.07% 10.12% 15.52% -73.54% 4.49%
Operating Cash Flow Growth		 -11.64% -83.71% -36.62% -8.75% -4.92% -9.56% 13.61% 10.08% 2.61% 21.32% 16.24%
Free Cash Flow Firm Growth		 -26.91% -22.02% 19.71% -22.01% -12.89% 22.55% 31.78% 43.69% 62.02% 3.52% 70.65%
Invested Capital Growth		 41.41% 91.69% -335.07% -12.12% 15.75% 21.85% -40.12% -27.61% -9.75% -34.77% 1,783.26%
Revenue Q/Q Growth		 -18.68% 19.70% 4.05% 5.20% 15.29% -4.00% 10.24% 19.66% 30.14% 22.58% -37.01%
EBITDA Q/Q Growth		 17.47% -113.14% 1,034.82% -12.87% 9.95% -6.76% -4.06% -3.46% 9.25% -11.94% 5.43%
EBIT Q/Q Growth		 14.72% -112.68% 1,046.22% -13.21% 11.95% -4.88% -8.30% -3.31% 10.15% -10.18% 6.54%
NOPAT Q/Q Growth		 14.72% 10.10% -31.43% -14.93% 13.37% -5.33% -7.68% -3.41% 36.04% -55.53% 6.71%
Net Income Q/Q Growth		 7.49% -110.18% 1,086.20% -17.87% 15.00% -5.05% -8.97% -3.44% -321.81% 144.68% 10.96%
EPS Q/Q Growth		 -7.64% -108.88% 1,059.76% -16.55% 15.20% -4.27% -8.61% -2.72% -316.18% 145.64% 11.31%
Operating Cash Flow Q/Q Growth		 16.28% -58.12% -16.02% 27.31% -37.77% -17.59% 7.65% 29.87% -43.86% 7.27% 3.88%
Free Cash Flow Firm Q/Q Growth		 5.32% -87.61% 32.02% -5.10% 8.97% -23.44% -3.32% 2.76% 37.55% -8.73% 14.72%
Invested Capital Q/Q Growth		 369.47% 126.27% -323.31% -48.65% 536.38% -67.79% -16.52% -32.37% 569.93% -84.17% 0.93%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 87.57% 88.26% 91.27% 82.65% 92.34% 91.75% 91.44% 83.49% 90.12% 90.42% 85.30%
EBITDA Margin		 -1,222.77% -1,204.90% 10,976.53% -1,221.75% -1,138.73% -1,457.89% -1,310.93% -1,388.78% -1,606.26% -2,303.41% -2,522.41%
Operating Margin		 -1,221.97% -1,165.30% -1,146.93% -1,228.29% -1,124.34% -1,496.23% -1,363.66% -1,396.01% -1,615.49% -2,300.97% -2,590.73%
EBIT Margin		 -1,221.97% -1,165.30% 11,003.18% -1,209.96% -1,124.34% -1,472.11% -1,347.47% -1,371.57% -1,588.68% -2,300.97% -2,559.95%
Profit (Net Income) Margin		 -1,023.25% -899.56% 10,574.69% -1,115.71% -995.84% -1,350.70% -1,234.27% -1,248.60% -1,444.43% 847.47% -2,325.00%
Tax Burden Percent		 98.62% 93.02% 94.69% 100.00% 98.04% 100.00% 100.00% 100.00% 100.00% 92.47% 100.00%
Interest Burden Percent		 84.91% 82.99% 101.49% 92.21% 90.35% 91.75% 91.60% 91.03% 90.92% -39.83% 90.82%
Effective Tax Rate		 0.00% 0.00% 5.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -885.75% -4,384.34% 0.00% -1,655.05% -838.03% -6,628.12% -1,188.78% -955.04% -797.05% -6,770.51% -1,586.34%
ROIC Less NNEP Spread (ROIC-NNEP)		 -884.38% -4,383.57% 0.00% -1,652.28% -836.04% -6,625.86% -1,186.60% -953.26% -795.45% -6,781.90% -1,584.86%
Return on Net Nonoperating Assets (RNNOA)		 855.76% 4,358.26% 0.00% 1,619.21% 810.11% 6,596.48% 1,162.96% 934.44% 776.32% 6,754.46% 1,570.14%
Return on Equity (ROE)		 -29.99% -26.08% 53.65% -35.85% -27.92% -31.64% -25.82% -20.60% -20.73% -16.04% -16.20%
Cash Return on Invested Capital (CROIC)		 -1,265.38% -5,946.11% 0.00% -1,730.53% -1,010.70% -6,485.22% -1,344.26% -1,239.90% -971.77% -5,585.20% -1,250.57%
Operating Return on Assets (OROA)		 -37.63% -32.71% 258.43% -40.77% -33.04% -36.30% -29.60% -23.64% -24.29% -24.48% -18.68%
Return on Assets (ROA)		 -31.51% -25.25% 248.37% -37.59% -29.27% -33.30% -27.12% -21.52% -22.09% 9.02% -16.96%
Return on Common Equity (ROCE)		 -29.99% -26.08% 53.65% -35.85% -27.92% -31.64% -25.82% -20.60% -20.73% -16.04% -16.20%
Return on Equity Simple (ROE_SIMPLE)		 45.41% 0.00% 41.45% -55.25% -47.40% 0.00% -24.76% -21.78% -21.04% 0.00% -34.56%
Net Operating Profit after Tax (NOPAT)		 -75 -88 -97 -74 -64 -74 -71 -66 -63 -99 -64
NOPAT Margin		 -855.38% -815.71% -1,086.07% -859.80% -787.04% -1,047.36% -954.56% -977.21% -1,130.85% -2,300.97% -1,813.51%
Net Nonoperating Expense Percent (NNEP)		 -1.37% -0.77% 82.53% -2.77% -1.98% -2.26% -2.18% -1.78% -1.61% 11.39% -1.48%
Return On Investment Capital (ROIC_SIMPLE)		 -5.09% -5.68% - - - -9.17% - - - -9.01% -
Cost of Revenue to Revenue		 12.43% 11.74% 8.73% 17.35% 7.66% 8.25% 8.56% 16.51% 9.88% 9.58% 14.70%
SG&A Expenses to Revenue		 475.90% 481.80% 429.91% 412.49% 378.73% 497.04% 348.99% 453.05% 505.74% 760.35% 828.30%
R&D to Revenue		 833.64% 771.76% 808.29% 898.44% 837.95% 1,090.93% 1,106.11% 1,026.45% 1,199.88% 1,631.04% 1,847.72%
Operating Expenses to Revenue		 1,309.53% 1,253.56% 1,238.20% 1,310.93% 1,216.68% 1,587.98% 1,455.10% 1,479.50% 1,705.62% 2,391.39% 2,676.02%
Earnings before Interest and Taxes (EBIT)		 -107 -125 986 -104 -92 -105 -100 -92 -89 -99 -90
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -107 -129 984 -105 -93 -104 -97 -93 -90 -99 -89
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.14 1.22 1.55 3.71 2.20 1.53 1.56 1.63 1.23 1.40 1.48
Price to Tangible Book Value (P/TBV)		 1.14 1.22 1.55 3.71 2.20 1.53 1.56 1.63 1.23 1.40 1.48
Price to Revenue (P/Rev)		 45.33 51.35 76.90 78.20 55.58 46.40 57.41 78.13 66.78 108.35 156.12
Price to Earnings (P/E)		 2.52 2.78 3.75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 39.67% 35.95% 26.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 6.07 38.32 0.00 118.49 31.05 94.14 35.09 36.22 10.12 116.69 21.72
Enterprise Value to Revenue (EV/Rev)		 6.86 9.37 26.38 57.58 31.29 16.34 21.11 31.13 13.62 31.31 52.79
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.97 -0.99 -1.01 -0.98 -0.97 -1.00 -0.98 -0.98 -0.98 -1.00 -0.99
Leverage Ratio		 1.09 1.11 1.11 1.14 1.12 1.14 1.13 1.12 1.11 1.12 1.11
Compound Leverage Factor		 0.92 0.92 1.13 1.05 1.02 1.04 1.03 1.02 1.01 -0.45 1.01
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.99%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 11.61 9.48 11.62 11.72 8.32 5.33 6.33 7.51 6.51 6.67 7.05
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 18.50 11.90 8.99 10.09 12.84 12.27 12.06 13.73 17.55 13.30 14.65
Quick Ratio		 17.12 11.06 8.44 9.16 11.64 11.47 11.10 12.78 16.43 12.54 13.68
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -87 -92 -49 -72 -68 -75 -61 -59 -61 -97 -89
Operating Cash Flow to CapEx		 -14,554.70% -13,771.15% -20,099.76% -45,942.41% -98,878.22% -30,977.78% 0.00% 0.00% -38,226.10% 0.00% -187,765.79%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.03 0.03 0.02 0.03 0.03 0.02 0.02 0.02 0.02 0.01 0.01
Accounts Receivable Turnover		 10.90 10.55 15.31 10.41 11.24 10.70 7.10 6.15 4.95 4.33 1.58
Inventory Turnover		 0.18 0.18 0.16 0.17 0.17 0.21 0.24 0.26 0.28 0.00 0.00
Fixed Asset Turnover		 2.94 2.70 2.30 1.93 1.65 1.40 1.14 0.86 0.75 0.55 0.39
Accounts Payable Turnover		 0.37 0.32 0.23 0.31 0.30 0.20 0.23 0.27 0.19 0.10 0.12
Days Sales Outstanding (DSO)		 33.49 34.60 23.84 35.05 32.47 34.13 51.40 59.36 73.73 84.38 231.24
Days Inventory Outstanding (DIO)		 2,079.43 2,045.93 2,284.67 2,163.56 2,127.97 1,746.32 1,512.97 1,389.24 1,318.01 0.00 0.00
Days Payable Outstanding (DPO)		 982.22 1,157.79 1,589.96 1,183.22 1,224.31 1,798.77 1,596.27 1,367.06 1,922.29 3,782.38 2,929.47
Cash Conversion Cycle (CCC)		 1,130.70 922.73 718.55 1,015.40 936.13 -18.32 -31.90 81.54 -530.54 -3,698.00 -2,698.23
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 42 8.93 -34 15 30 4.66 14 17 26 3.82 24
Invested Capital Turnover		 1.04 5.37 -3.37 1.92 1.06 6.33 1.25 0.98 0.70 2.94 0.87
Increase / (Decrease) in Invested Capital		 12 4.27 -48 -2.10 4.03 0.84 -9.69 -6.60 -2.77 -2.04 26
Enterprise Value (EV)		 254 342 867 1,803 920 438 507 627 259 446 524
Market Capitalization		 1,679 1,874 2,528 2,448 1,634 1,245 1,380 1,574 1,270 1,543 1,550
Book Value per Share		 $25.60 $27.02 $28.59 $11.63 $13.19 $14.51 $15.91 $17.35 $18.75 $20.03 $19.16
Tangible Book Value per Share		 $25.60 $27.02 $28.59 $11.63 $13.19 $14.51 $15.91 $17.35 $18.75 $20.03 $19.16
Total Capital		 1,467 1,541 1,627 661 744 811 887 964 1,037 1,101 1,050
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1,425 -1,532 -1,661 -645 -714 -806 -872 -947 -1,011 -1,097 -1,026
Capital Expenditures (CapEx)		 0.77 0.97 0.42 0.16 0.10 0.23 -0.81 -0.00 0.25 -0.85 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 23 -9.27 -50 -0.40 14 -11 -1.56 -0.47 7.34 -13 3.66
Debt-free Net Working Capital (DFNWC)		 916 884 955 569 612 766 646 702 747 770 731
Net Working Capital (NWC)		 916 884 955 569 612 766 646 702 747 770 731
Net Nonoperating Expense (NNE)		 15 9.00 -1,045 22 17 22 21 18 18 -136 18
Net Nonoperating Obligations (NNO)		 -1,425 -1,532 -1,661 -645 -714 -806 -872 -947 -1,011 -1,097 -1,026
Total Depreciation and Amortization (D&A)		 -0.07 -4.25 -2.39 -1.02 -1.18 1.01 2.70 -1.16 -0.99 -0.11 1.32
Debt-free, Cash-free Net Working Capital to Revenue		 61.77% -25.39% -152.17% -1.28% 47.43% -41.19% -6.50% -2.32% 38.61% -91.12% 36.85%
Debt-free Net Working Capital to Revenue		 2,474.01% 2,423.27% 2,904.50% 1,819.11% 2,081.20% 2,855.31% 2,688.00% 3,484.88% 3,925.66% 5,408.31% 7,364.94%
Net Working Capital to Revenue		 2,474.01% 2,423.27% 2,904.50% 1,819.11% 2,081.20% 2,855.31% 2,688.00% 3,484.88% 3,925.66% 5,408.31% 7,364.94%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.55) ($1.65) $16.65 ($1.69) ($1.45) ($1.71) ($1.64) ($1.51) ($1.47) $0.68 ($1.49)
Adjusted Weighted Average Basic Shares Outstanding		 57.46M 56.81M 56.94M 56.80M 56.38M 55.65M 55.80M 55.60M 55.27M 54.79M 54.84M
Adjusted Diluted Earnings per Share		 ($1.55) ($1.44) $16.22 ($1.69) ($1.45) ($1.71) ($1.64) ($1.51) ($1.47) $0.68 ($1.49)
Adjusted Weighted Average Diluted Shares Outstanding		 57.46M 57.89M 58.43M 56.80M 56.38M 55.65M 55.80M 55.60M 55.27M 54.79M 54.84M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 57.92M 57.30M 57.03M 56.89M 56.77M 56.19M 55.89M 55.74M 55.58M 55.29M 54.94M
Normalized Net Operating Profit after Tax (NOPAT)		 -75 -88 -97 -74 -64 -74 -71 -66 -63 -69 -64
Normalized NOPAT Margin		 -855.38% -815.71% -1,086.07% -859.80% -787.04% -1,047.36% -954.56% -977.21% -1,130.85% -1,610.68% -1,813.51%
Pre Tax Income Margin		 -1,037.61% -967.06% 11,167.28% -1,115.71% -1,015.79% -1,350.70% -1,234.27% -1,248.60% -1,444.43% 916.45% -2,325.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Agios Pharmaceuticals' Financials

When does Agios Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Agios Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Agios Pharmaceuticals' net income changed over the last 10 years?

Agios Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of $673.73 million in 2024, falling from -$53.50 million in 2014. The previous period was -$352.09 million in 2023. Check out Agios Pharmaceuticals' forecast to explore projected trends and price targets.

What is Agios Pharmaceuticals's operating income?
Agios Pharmaceuticals's total operating income in 2024 was -$425.74 million, based on the following breakdown:
  • Total Gross Profit: $32.33 million
  • Total Operating Expenses: $458.07 million
How has Agios Pharmaceuticals revenue changed over the last 10 years?

Over the last 10 years, Agios Pharmaceuticals' total revenue changed from $65.36 million in 2014 to $36.50 million in 2024, a change of -44.2%.

How much debt does Agios Pharmaceuticals have?

Agios Pharmaceuticals' total liabilities were at $122.24 million at the end of 2024, a 3.1% decrease from 2023, and a 81.0% increase since 2014.

How much cash does Agios Pharmaceuticals have?

In the past 10 years, Agios Pharmaceuticals' cash and equivalents has ranged from $14.03 million in 2014 to $203.13 million in 2021, and is currently $76.25 million as of their latest financial filing in 2024.

How has Agios Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, Agios Pharmaceuticals' book value per share changed from 12.24 in 2014 to 27.02 in 2024, a change of 120.8%.


Related Companies

This page (NASDAQ:AGIO) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored